Amr 2018-2022 Actionplan Progressreport en

PROGRESS REPORT 2017 EU AMR ACTION PLAN
Last update: Q4 2020 1
1. MAKING THE EU A BEST PRACTICE REGION

1.1 BETTER EVIDENCE AND AWARENESS OF THE CHALLENGES OF AMR
CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES
• Strengthen One Health surveillance and

2017 2018 2019 2020 2021 2022
reporting of AMR and antimicrobial use
Review EU implementing legislation on monitoring AMR in zoonotic Mandate to EFSA Adoption of the new
and commensal bacteria in farm animals and food. EFSA opinion
for technical advice legislation
New implementing
Review EU implementing legislation on reporting communicable
act with updated
diseases in humans.
AMR case definitions
Mandate to EFSA
for technical
Identify and assess under the Animal Health Law, resistant bacteria advice once list
that cause transmissible animal diseases and, if necessary, develop of transmissible
harmonised rules for their surveillance. disease is adopted
under Animal
Health Law
Improve AMR detection in the human health sector by providing EU health programme funding to support AMR networking
EU support for networking collaboration and reference laboratory collaboration and reference laboratory
activities. activities in human health
Consider options for the harmonised monitoring of AMR in the

Linked to the EU strategic approach to pharmaceuticals in the environment (see action 1.4)
environment.
• Benefit from the best evidence-based

2017 2018 2019 2020 2021 2022
analysis and data
Provide evidence-based data on possible links between the Mandate to EFSA/
Second JIACRA
consumption of antimicrobial agents and the occurrence of ECDC/EMA for a 3rd 3rd JIACRA report*
report
antimicrobial resistance in humans and food-producing animals. JIACRA report
Define a limited number of key outcome indicators for AMR and EFSA/ECDC/EMA
antimicrobial consumption. report on indicators
* Planned or ongoing
2017 2018 2019 2020 2021 2022
Support the development of a model aimed at helping Member

Further work by OECD, supported by the EU Health Programme
States to assess the economic burden of AMR imposes on people Publication of the
to extend the model and to provide support to Member States in
and to estimate the cost-effectiveness of their national policies to OECD model
using the model*
reduce it.
• Increase awareness and understanding 2017 2018 2019 2020 2021 2022
Provide insights into reported public use of and knowledge about Eurobarometer Eurobarometer
antimicrobials through Eurobarometer surveys. in MS in MS
Support Member States’ national awareness-raising efforts

with specific communication tools targeting key audiences and
EAAD EAAD EAAD EAAD EAAD EAAD
contribute to the annual European Antibiotic Awareness Day
(EAAD).
1.2 BETTER COORDINATION AND IMPLEMENTATION OF EU RULES TO TACKLE AMR

• Improve the coordination of Member
2017 2018 2019 2020 2021 2022
States’ One Health responses to AMR
Make available regular information on AMR in the context of the
2nd meeting 4th meeting 6th meeting*
AMR One Health network, which gives an overview of the AMR
3rd meeting 5th meeting 7th meeting*
epidemiological situation at Member State and EU level.
Support the implementation of national One Health action plans

Joint One Health Joint One Health Joint One Health Joint One Health
through joint Commission and the ECDC visits to Member States
visits with ECDC visits with ECDC visits with ECDC visits with ECDC*
upon request.
Launch a joint action to tackle AMR and healthcare-associated

Final conference
infections to support collaborative activities and policy Launch Interim reports*
and report*
development by Member States.
2017 2018 2019 2020 2021 2022
Make increased use of the EU Health Security Committee and the

Commission Working Group on AMR in the veterinary and food Regular exchanges on AMR in HSC
areas to strengthen coordination and to share information.
Meeting of working Meetings of Meeting of

group on AMR working group on working group on
in food AMR in food AMR in food*
Seek to co-fund and collaborate with the WHO on activities to

help EU Member States develop and implement national One New WHO EURO activities co-funded by EU health programme
Health action plans against AMR.
• Better implementation of EU rules
Assess the effectiveness of the implementation of EU legislation Interim Overview

Overview report
on, inter alia, monitoring AMR in food-producing animal report
populations and food by continuing to carry out regular audits in
Member States. Audits Audits
Develop training programmes on AMR for Member State

competent authorities under the Better Training for Safer Food BTSF training activities
(BTSF) initiative and for health professionals.
SRSS support
Advise Member States on the possibility to use the Structural
presented to MSs in
Reform Support Service (SRSS) funding to Member States for
the AMR One Health
designing and implementing policies against AMR.
network
1.3 BETTER PREVENTION AND CONTROL OF AMR
• Strengthen infection prevention and 2017 2018 2019 2020 2021 2022
control measures
Work by OECD
supported by EU
health programme
to report on cost
effectiveness of
Support good practices in infection prevention and control AMR/infection
in hospital environments. prevention
measures including
hand hygiene and
hospital cleaning
Infection control training to be carried out by ECDC and WHO*
Report from
Report from
INTEGRATE joint
HA-REACT joint
action from EU
action from EU
health programme
Health programme
Support activities for infection prevention and control on integrating
on HIV and co-
in vulnerable groups, in particular to tackle resistant prevention, testing
infection prevention
tuberculosis strains. and link to care
and harm reduction
strategies across
which includes
HIV, viral hepatitis,
activities to address
TB and STIs in
tuberculosis
Europe*
Part of Joint Action Vaccination*

Promote the uptake of vaccination in humans to prevent
infections and subsequent use of antimicrobials. Part of policy initiative on vaccination (Council Recommendation on
strengthened cooperation against vaccine preventable diseases)*
2017 2018 2019 2020 2021 2022
Improve the microbiota of animals through

autorisation of several feed additives
Continue to promote animal husbandry, including aquaculture H2020 research

and livestock farming systems, and feeding regimes which projects launched:
AMR related
support good animal health and welfare to reduce antimicrobial DISARM,
workshop
consumption. ROADMAP and
HealthyLivestock
Implementation of existing policy on biosecurity AGRI action
• Promote the prudent use of antimicrobials 2017 2018 2019 2020 2021 2022
Forthcoming veterinary medicinal products and medicated feed

Regulations
Regulations containing concrete restrictions for the prophylactic
adopted
and metaphylactic use of antimicrobials. Moreover, work towards
(as of 2022)
EU implementing and delegated acts established in these Drafting of the acts
Regulations include a list of antimicrobials reserved for human and consultation
Implementing and
use, drawing up a list of antimicrobials that cannot be used with MS and
delegated acts to
under ‘cascade use’, limits for residues of antimicrobials in feed, stakeholders*
be adopted
requirements for animals or products of animal origin exported
as per deadlines in
from third countries and methods for data gathering and reporting
those Regulations
on the sales and use of antimicrobials.
Develop EU guidelines for the prudent use of antimicrobials in EU guidelines

human medicine. published
Fact-finding Fact-finding
missions on prudent missions on prudent
Overview report
use in veterinary use in veterinary
Assist Member States implement EU guidelines for the prudent
sector sector
use of antimicrobials in veterinary medicine.
Interim Overview
report
1.4 BETTER ADDRESSING THE ROLE OF THE ENVIRONMENT
2017 2018 2019 2020 2021 2022
EMA review
of medicines
containing
Exploratory meeting fosfomycin
EMA finalised with EMA on the
Encourage the EMA to review all available information on the a review of the topic of availability Regular update
benefits and risks of older antimicrobial agent vancomycin- of veterinary meetings with
containing medicines antimicrobials and EMA on the topic
their prudent use of availability
of veterinary
antimicrobials and
their prudent use*
EU strategic
approach to
Adopt an EU strategic approach to pharmaceuticals in the Implementation of EU strategic approach to pharmaceuticals
pharmaceuticals
environment. in the environment (PIE)
in the environment
(PIE) adopted
Project to
Maximise the use of data from existing monitoring to improve
promote IPCHeM
knowledge, including by using the Information Platform for
in regulatory
Chemical Monitoring (IPCheM).
processes*
Video material
Reinforce the role of the Scientific Committee on Health,
describing the role
Environmental and Emerging Risks (SCHEER) in providing scientific
of SCHEER circulated
advice to the European Commission on environment-related AMR
to relevant sectors in
issues.
the Commission
1.5 A STRONGER PARTNERSHIP AGAINST AMR AND BETTER
AVAILABILITY OF ANTIMICROBIALS
2017 2018 2019 2020 2021 2022
AMR discussed in
the plenary of the
advisory group of
the food chain and
animal and plant
health
Engage with and support collaboration among key stakeholders in EMA information
the human health, animal health, food, water and environmental session on AMR
sectors to encourage the responsible use of antimicrobials and (EMA Working Party
appropriate handling of waste material. with Patients’
and Consumers’
Organisations (PCWP)
and Healthcare
Professionals’
Organisations (HCPWP))
BTSF training activities

2017 2018 2019 2020 2021 2022
Multi-stakeholder
conference on
Discussion in the the themes
IVD Technical of availability
Group (IVD TG) of veterinary
and possibly in the antimicrobials
Work with stakeholders to ensure the availability of human and Medical Device (old, new and
veterinary antimicrobials and continued access to established Coordination Group future) and on their
products; provide incentives to increase the uptake of diagnostics, on how to promote prudent use, at EU
antimicrobial alternatives and vaccines. the uptake of level but also in the
diagnostics context of broader
international
cooperation*
Implementation of Regulation (EU) 2017/746 on in vitro diagnostic medical devices
Presidency Safer
Europe Without
Reduce the scope for falsified medicines by assisting Member Falsified Medicines
States and stakeholders in the successful implementation of the Conference
safety features (unique identifier). organised by
industry and the
Estonian Presidency
2017 2018 2019 2020 2021 2022
Conference
organised by DIA
(Drug information Regular Commission expert group on the
Reduce the scope for falsified medicines by assisting Member Association) with implementation of the safety features*
States and stakeholders in the successful implementation of the pharmaceutical
safety features (unique identifier). industry
Update of the Q&A interpretative document

on the safety features*
Exploratory
meeting* (see
Discuss the availability of veterinary antimicrobials to tackle
above mentioned
AMR in the Veterinary Pharmaceutical Committee.
multistakeholders
conference)
2. BOOSTING RESEARCH, DEVELOPMENT AND INNOVATION ON AMR

2.1 IMPROVE KNOWLEDGE ON DETECTION, EFFECTIVE INFECTION CONTROL AND SURVEILLANCE
2017 2018 2019 2020 2021 2022
Launch of One
Funding of research Launch of Call
Health EJP which
projects under the topic on clinical
includes research
ERA- NET SusAn on management of
on new intervention
animal production AMR
tools on AMR
Funding of projects
coming out of Call
topic SFS-46-2017
on alternative
production systems
Support research into the development and assessment of to address anti-
interventions that prevent the development and spread of AMR. microbial drug
usage, animal
welfare and the
impact on health
Funding decision
on projects from
the JPIAMR 5th
call on prevention
and intervention
strategies to control
AMR infections
Report of projects
Funding decision on
selected under
project addressing
3rd JPIAMR ERA-
Support research into understanding the epidemiology of AMR, in the clinical burden
NET Co-fund call
particular the pathways of transmission between animals of Clostridium
to bridge the
and humans, and their impact. difficile infection
knowledge gap on
under under IMI2,
AMR transmission
Call 9
mechanisms
2017 2018 2019 2020 2021 2022
Reporting
COMPARE, on the
Launch of One
rapid identification,
Health EJP which
containment
includes research
and mitigation
on early signalling
of emerging
and assessing
infectious diseases
zoonotic threats
and foodborne
outbreaks*
Support research into the development of new tools for
early (real-time) detection of resistant pathogens in humans Reporting
and animals. DIAGORAS, on
bedside diagnosis
Launch of Call topic
of oral and
SC1-BHC-13-2019,
respiratory tract
on mining of big
infections, and
data for early
identification
detection of
of antibiotic
infectious disease
resistances for
threats
personalised
monitoring and
treatment

Support research into new eHealth solutions to improve SC1-DTH-10-2019-
prescription practices, self-management of health, care 2020, on digital
solutions, and improve awareness of AMR. solutions for health
and care services
2.2 DEVELOP NEW THERAPEUTICS AND ALTERNATIVES
2017 2018 2019 2020 2021 2022
Funding decision
on EDCTP2 projects Reporting of project Launch of IMI2
Loans awarded under Reporting of project
on treatments PneumoNP on call topics on
IDFF to development anTBiotic progressing
for cryptococcal nanotherapeutics development of new
of new antimicrobials TB drug candidates
meningitis, malaria, to treat antibiotic antimicrobials and
and alternative to clinical proof of
HIV, tuberculosis and resistant Gram- alternative products
products* concept
reproductive tract Negative pneumonia for humans*
infections
Reporting of
project NAREB on
nanotherapeutics for Reports of projects from 1st and 2nd join
antibiotic resistant transnational calls of JPIAMR
emerging bacterial
pathogens
Support research into the development of new antimicrobials Launch of Call topics
and alternative products for humans and animals as well as the SC1-BHC-14-2019
repurposing of old antimicrobials or the development of new on stratified
combination therapies. host-directed Reporting of IMI
approaches to ND4BB projects on
improve prevention, development of new
treatment and/or antimicrobials and
cure of infectious alternative products
diseases and SC2- for humans*
SFS-11-2019- 2019
on antimicrobials and
animal production
Reporting of
project FormAMP
on innovative
nanoformulation
design of
antimicrobial
peptides
2017 2018 2019 2020 2021 2022
Reporting of
Support SMEs in their R&D efforts towards innovative and/ projects from SME
or alternative therapeutic approaches for the treatment or Instrument, on
prevention of bacterial infections. development of new
antimicrobials and
alternative products*
Launch of IMI2
call topics on
development of
new antimicrobials
including facilitating
Facilitate sharing of antimicrobial research data among relevant data sharing
stakeholders.
Reporting of IMI
ND4BB project
TRANSLOCATION on
antibacterial drug
discovery

Reporting of IMI
SC1-HCO-08-2018
ND4BB project
Support the establishment of a European-wide sustainable on the creation of
COMBACTE on the
clinical research network. a European wide
development of
sustainable clinical
new antibacterial
research network for
treatments
infectious diseases
Reporting of
Support research and innovation to promote the use of digital Biotechnology (LEIT)
technologies supporting the development of new therapeutics project DD-DeCaF
and alternatives. on optimisation of
-omics data
2.3 DEVELOP NEW PREVENTIVE VACCINES
2017 2018 2019 2020 2021 2022
Reporting of projects
from Call topic
SC1- PM-16-2017
on in-silico trials
for developing and
assessing biomedical
products*
Reporting of
Reporting of the Reporting of the
Launch of Call projects OptiMalVax
Launch of Call Topic European AIDS European HIV
Topics SC1- and MultiViVax on
SC1-BHC-15-2018, Vaccine Initiative Vaccine Alliance
BHC-14-2019, Malaria vaccine
on new anti- (EAVI) 2020* (EHVA)
on stratified development
infective agents
host-directed
(including vaccines)
approaches to Reporting of
for prevention and/ Reporting of projects
improve prevention, project TracVac
or treatment of TBVAC2020 and EMI-
treatment and/or on Developing
neglected infectious TB on advancing
cure of infectious a Chlamydia
diseases tuberculosis vaccine
diseases, SC2- Trachomatis
candidates
SFS-31-2019 (ERA- vaccine
Continue to support research into the development of new
NET) on veterinary
effective preventive vaccines for humans and animals.
vaccinology and Reporting of project
SC2-SFS-12-2019 Loans awarded
SAPHIR on novel
on swine fever under IDFF to
vaccine strategies
vaccines development of
for animal
new vaccines*
production
Reporting
MycoSynVac, on
development of
a Mycoplasma
vaccine for animal
use*
2.4 DEVELOP NOVEL DIAGNOSTICS
2017 2018 2019 2020 2021 2022
Launch of Call Topic

Support increasing the knowledge base concerning the barriers SFS-11-2018-2019,
that influence the wider use of vaccination in medical and on antimicrobials
veterinary practice. and livestock
production
Reporting of project
Launch of IMI2 Reporting of project Reporting of poject
FAPIC on developping
call, on diagnostics VIROGENESIS on Poc-ID on Point-of-
a fast assay for
development and virus discovery and Care diagnostics for
pathogen identification
validation epidemic tracing Infectious Diseases*
and characterisation*
Launch of One
Health EJP, incl. Loans awarded
under IDFF to
research on new
development of new
Support research into the development of new diagnostic diagnostic tools on diagnostic tools*
tools in particular on-site tests in humans and animals. AMR
Reporting of
EDCTP2 projects,
on diagnostic tools
for poverty-related
diseases*
Reporting PREPARE,
on outbreak
preparedness*
Reporting of
projects from SME
Instrument, on
Support the use of IT solutions in developing tools for IT solutions and
diagnosing human and animal infections. tools to support
diagnosing human
and animal
infections*
2.5 DEVELOP NEW ECONOMIC MODELS AND INCENTIVES
2017 2018 2019 2020 2021 2022

Encourage the uptake of diagnostics in medical and SC1-HCO-12-2018,
veterinary practice. on Innovation
Procurement
Increase the evidence base for understanding the societal costs Reporting of IMI
and benefits of different strategies for fighting AMR. DRIVE-AB project
Reporting of IMI
Support research into the development of new economic models, DRIVE-AB project
exploring and analysing incentives to boost the development of
new therapeutics, alternatives, vaccines and diagnostics. TATFAR discussion
on incentives
Report from Study on the

Analyse EU regulatory tools and incentives – in particular orphan the European economic impact of Evaluation of
and paediatric legislation – to use them for novel antimicrobials Commission to the the supplementary Study on orphan the orphan
and innovative alternative medicinal products that currently do European Parliament protection certificate, medicinal products and paediatric
and the Council on pharmaceutical legislation medicines
not generate sufficient returns on investment.
the 10 years of the incentives and legislation*
paediatric Regulation rewards in Europe
Encourage Member States to explore results and

recommendations of EU research projects on new Discussion with Member States in the
Pharmacuetical Committee
economic business models.

Develop new or improved methodological HTA approaches SC1-BHC-26-2018,
and foster methodological consensus-building. on HTA research to
support evidence-
based healthcare
2.6 CLOSE KNOWLEDGE GAPS ON AMR IN THE ENVIRONMENT

AND ON HOW TO PREVENT TRANSMISSION
2017 2018 2019 2020 2021 2022
Reporting of Reports of projects

Support research into knowledge gaps on the release of resistant Launch of One project EFFORT from JPIAMR 3rd
microorganisms and antimicrobials into the environment and their Health EJP, incl.
on microbial drug ERA- NET Co-fund
research on
spread. resistance and call on transmission
resistance spread
transmission dynamics
Explore risk assessment methodologies to evaluate the risks to Launch of One

human and animal health from the presence of antimicrobials in Health EJP, incl. Implementation of Commission strategic approach to
the environment. research on pharmaceuticals in the environment (PIE)*
resistance spread
Support research into and the development of new tools for

monitoring antimicrobials and microorganisms resistant against Implementation of Commission strategic approach to
antimicrobials in the environment. pharmaceuticals in the environment (PIE)*
Support the development of technologies that enable efficient

and rapid degradation of antimicrobials in wastewater and the ERA-NET for JPI
environment and reduce the spread of AMR. Water and JPIAMR
3. SHAPING THE GLOBAL AGENDA

3.1 A STRONGER EU GLOBAL PRESENCE
2017 2018 2019 2020 2021 2022
Signature of a
letter of intent New CODEX
for reinforced guidelines on
cooperation integrated
between FAO and Involvement of FAO in new BTSF activities for non-EU countries
monitoring and
EC between FAO DG surveillance of
and V. Andriukaitis
foodborne AMR
Continue to actively contribute to the normative work of the WHO, Commission
the OIE, the FAO, and the Codex Alimentarius on the development
of ambitious international frameworks and standards/norms/ Review upcoming
guidelines/methodologies related to AMR. normative work
(e.g. as outlined in
Revised CODEX
resolution of the
code of practice to
World Health
minimize AMR
Assembly)
and assess EC
involvement
Reinforce technical cooperation with the WHO and its members in

key areas of the WHO Global Action Plan on AMR.
2017 2018 2019 2020 2021 2022
Promotion of the
new EU Action Plan Explore the needs
Boost support for the International Conference on the Text on AMR in
against AMR during to update existing
Harmonisation of Technical Requirements for the Registration the UN political
the IPRF meeting VICH guidelines and
of Pharmaceuticals for Human Use (ICH) and the Veterinary declaration on
in the margins of other possibilities
International Conference on the Harmonisation (VICH) on relevant Universal Health
the ICH meeting supporting
international guidelines/standards/norms related to AMR. Coverage
in Geneva in harmonisation*
November 2017
AMR featuring
in the G7
Health Minister
AMR on G7 and AMR on G7 and AMR on G20
Communique
G20 Agenda G20 Agenda Agenda
and G20 Health
Ministers'
Declaration
Work towards continued high-level political attention and
commitment to AMR action, including in the United Nations Approval by G7
forums, the G7 and the G20. CVOs of a common
approach on
the definitions
of therapeutic,
responsible and
prudent use of
antimicrobials in
animals
Look for synergies with the UN Strategic Approach to International EU Chemical

Chemicals Management’s work on the emerging policy issue of Implemantation of EU Chemical
Startegy for
Startegy for Sustainability*
pharmaceuticals in the environment. Sustainability
Analyse the feasibility of setting up a global AMR clinical studies

network in collaboration with G7 members.
2017 2018 2019 2020 2021 2022
Updated TATFAR Develop actions

Continue and strengthen ongoing collaboration within the
work plan and and deliverables for
Transatlantic Taskforce on Antimicrobial Resistance (TATFAR),
deliverables new TATFAR work
which includes the EU, the USA, Canada, and Norway.
plan 2021-2025*
4th tripartite
meeting between
Promote international regulatory convergence between the EMA
PMDA, EMA, and
and other regulatory agencies such as the US Food and Drug
FDA to discuss
Administration (FDA) and the Japan Pharmaceuticals and Medical
convergence on
Devices Agency (PMDA) on development plans for new promising
approaches for
antimicrobials.
the evaluation of
antibacterial drugs*
3.2 STRONGER BILATERAL PARTNERSHIPS FOR STRONGER COOPERATION
2017 2018 2019 2020 2021 2022
AMR cooperation
Discussions with
article agreed
Mercosur on SPS
between EU and
issues
Indonesia*
AMR cooperation
article agreed
between EU and
Malaysia*
Advocate EU standards and measures for tackling AMR in trade
agreements and incorporate them into cooperative arrangements
AMR cooperation
in trade agreements.
article agreed
between EU
and India*
Trade discussions
with ASEAN
countries*
FTA negotiations
with Australia and
New Zealand*
IMPROVE KNOWLEDGE ON DETECTION, EFFECTIVE INFECTION CONTROL AND SURVEILLANCE
2017 2018 2019 2020 2021 2022
Seminars on AMR
Seminars on AMR
with Argentina, AMR activities with
with Paraguay, Peru
Brazil, Chile & China and India*
& Uruguay
Colombia
Overview report
Seminar with regarding national Follow-up seminars
Engage with major global players and strategic countries (e.g. India on the use policies and in South East Asia AMR activities in South East Asia
Brazil, China, India), contributing towards achieving objectives of of veterinary measures against including Australia and South America
the WHO global action plan on AMR. medicines and AMR AMR in third and New Zealand*
countries
Identification
AMR activities in
mission on AMR
Latin American
cooperation with
countries under FPI
South-American
project
partner countries
ECDC/EFSA and EU-

Support EU candidate countries, potential candidate countries Enlargement multi-
and neighbouring countries to which the ENP applies in the country workshop /
alignment with, and capacity building for the implementation of ECDC/EFSA and EU-
EU legislation related to AMR and EU standards. ENP multi-country
workshop
Invite the European Parliament, Member States and stakeholders

to share views on actions to be taken to ensure that efforts to
combat AMR made by EU producers, including farmers, do not
place them at a competitive disadvantage.
3.3 COOPERATING WITH DEVELOPING COUNTRIES
2017 2018 2019 2020 2021 2022
Implementation
Continue to contribute to reducing AMR in least developed
through
countries through infectious disease programmes such as the
Commission
Global Alliance for Vaccines and Immunisations (GAVI)
pledges
Assist in the development of AMR strategies in the areas of food

safety and animal health through regional training workshops on New BTSF activities for non-EU countries
AMR
Support partner countries’ policy initiatives on AMR, where

Through a pilot project on mapping the global threat of AMR, DEVCO supports WHO to develop a point prevalence protocol for
appropriate, through international cooperation and development
undertaking surveys on prescribing and use of antimicrobial medicines in hospital setting, build capacity to implement antimicrobial
instruments (e.g. Global Public Goods & Challenges, the European
stewardship programmes in hospitals in SSA, address the prevention, detection and response to substandard and falsified products
Development Fund).
Support the development of resilient health systems in partner Supporting WHO for strengthened health systems through development funding
countries instruments at country and region levels
3.4 DEVELOPING A GLOBAL RESEARCH AGENDA
2017 2018 2019 2020 2021 2022
Improve global coordination of research activities. Launch of G20

Research hub
Reporting of project
Support the establishment of a virtual research institute EXEDRA on the
under JPIAMR. expansion of the
JPIAMR
Reporting of
EDCTP2 projects on
research capacity
development in
support of the EVD
response
Continue collaborative research with Sub-Saharan Africa in the
context of the European and Developing Countries Clinical Trial Reporting of
Partnership (EDCTP) in particular in relation to tuberculosis, HIV/ EDCTP2 projects
AIDS, malaria and neglected infectious diseases. on maximising
the impact of
EDCTP research
and translation of
research results
into policy and
practice
Foster international research collaboration on AMR in the

animal health sector in the STAR-IDAZ International
Research Consortium.

Amr 2018-2022 Actionplan Progressreport en

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Amr 2018-2022 Actionplan Progressreport en

Uploaded by

Copyright:

Available Formats

PROGRESS REPORT 2017 EU AMR ACTION PLAN

Last update: Q4 2020 1

1. MAKING THE EU A BEST PRACTICE REGION

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

• Strengthen One Health surveillance and

Consider options for the harmonised monitoring of AMR in the

• Benefit from the best evidence-based

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

2017 2018 2019 2020 2021 2022

Support the development of a model aimed at helping Member

Support Member States’ national awareness-raising efforts

1.2 BETTER COORDINATION AND IMPLEMENTATION OF EU RULES TO TACKLE AMR

Support the implementation of national One Health action plans

Launch a joint action to tackle AMR and healthcare-associated

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

2017 2018 2019 2020 2021 2022

Make increased use of the EU Health Security Committee and the

Meeting of working Meetings of Meeting of

Seek to co-fund and collaborate with the WHO on activities to

• Better implementation of EU rules

Assess the effectiveness of the implementation of EU legislation Interim Overview

Develop training programmes on AMR for Member State

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

Infection control training to be carried out by ECDC and WHO*

Part of Joint Action Vaccination*

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

2017 2018 2019 2020 2021 2022

Improve the microbiota of animals through

Continue to promote animal husbandry, including aquaculture H2020 research

Implementation of existing policy on biosecurity AGRI action

Forthcoming veterinary medicinal products and medicated feed

Develop EU guidelines for the prudent use of antimicrobials in EU guidelines

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

2017 2018 2019 2020 2021 2022

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

2017 2018 2019 2020 2021 2022

BTSF training activities

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

2017 2018 2019 2020 2021 2022

Implementation of Regulation (EU) 2017/746 on in vitro diagnostic medical devices

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

2017 2018 2019 2020 2021 2022

Update of the Q&A interpretative document

2. BOOSTING RESEARCH, DEVELOPMENT AND INNOVATION ON AMR

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

2017 2018 2019 2020 2021 2022

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

2017 2018 2019 2020 2021 2022

Launch of Call topic

2.2 DEVELOP NEW THERAPEUTICS AND ALTERNATIVES

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

2017 2018 2019 2020 2021 2022

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

2017 2018 2019 2020 2021 2022

Launch of Call topic

2.3 DEVELOP NEW PREVENTIVE VACCINES

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

2017 2018 2019 2020 2021 2022

2.4 DEVELOP NOVEL DIAGNOSTICS

CONCRETE ACTIVITIES TIMELINES AND DELIVERABLES

2017 2018 2019 2020 2021 2022

Launch of Call Topic

2.5 DEVELOP NEW ECONOMIC MODELS AND INCENTIVES